Mutual of America Capital Management LLC Trims Stock Position in Vericel Corporation $VCEL

Mutual of America Capital Management LLC trimmed its holdings in Vericel Corporation (NASDAQ:VCEL) by 8.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 153,609 shares of the biotechnology company’s stock after selling 14,798 shares during the period. Mutual of America Capital Management LLC owned 0.30% of Vericel worth $4,834,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its position in shares of Vericel by 244.6% in the second quarter. Allspring Global Investments Holdings LLC now owns 859,486 shares of the biotechnology company’s stock worth $35,755,000 after acquiring an additional 610,045 shares during the last quarter. Geneva Capital Management LLC raised its stake in Vericel by 30.7% during the second quarter. Geneva Capital Management LLC now owns 1,784,927 shares of the biotechnology company’s stock worth $75,949,000 after purchasing an additional 419,183 shares during the period. Conestoga Capital Advisors LLC boosted its holdings in shares of Vericel by 19.5% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 2,463,590 shares of the biotechnology company’s stock valued at $104,826,000 after purchasing an additional 401,990 shares during the last quarter. Champlain Investment Partners LLC increased its holdings in shares of Vericel by 62.5% during the 2nd quarter. Champlain Investment Partners LLC now owns 997,291 shares of the biotechnology company’s stock worth $42,435,000 after buying an additional 383,498 shares during the last quarter. Finally, Osterweis Capital Management Inc. acquired a new stake in shares of Vericel during the 2nd quarter worth $9,713,000.

Analyst Ratings Changes

VCEL has been the topic of a number of research analyst reports. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a report on Sunday, January 25th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Vericel in a research note on Monday, December 29th. Truist Financial dropped their target price on shares of Vericel from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Finally, Zacks Research cut shares of Vericel from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Vericel has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Vericel Stock Performance

VCEL stock opened at $36.50 on Friday. The firm has a market cap of $1.85 billion, a P/E ratio of 152.09 and a beta of 1.17. Vericel Corporation has a 1 year low of $29.24 and a 1 year high of $63.00. The stock has a 50-day simple moving average of $37.69 and a 200-day simple moving average of $36.29.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, November 6th. The biotechnology company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.12. Vericel had a net margin of 5.06% and a return on equity of 4.30%. The business had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $64.57 million. During the same period in the previous year, the company posted ($0.02) earnings per share. The business’s revenue for the quarter was up 16.6% compared to the same quarter last year. On average, equities research analysts predict that Vericel Corporation will post 0.14 EPS for the current year.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.